idarubicin has been researched along with Lymphoma, Non-Hodgkin in 52 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.92) | 18.7374 |
| 1990's | 26 (50.00) | 18.2507 |
| 2000's | 22 (42.31) | 29.6817 |
| 2010's | 2 (3.85) | 24.3611 |
| 2020's | 1 (1.92) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Li, Y; Liu, S; Tian, C; Wang, Y; Yang, H; Yu, Y; Yuan, T; Zhang, Y; Zhao, H; Zhao, Z | 1 |
| Brion, A; Chabin, M; Clavert, A; Colombat, P; Cumin, I; Delwail, V; Escoffre-Barbe, M; Gardembas, M; Ingrand, P; Lacotte-Thierry, L; Legouffe, E; Olivier, G; Solal-Celigny, P | 1 |
| Cen, J; Qian, L; Shen, J; Yin, W; Zhou, C | 1 |
| Handa, H; Isozumi, K; Komatsumoto, S; Motohashi, S; Nara, M | 1 |
| Arlt, A; Bartscht, T; Bruhn, HD; Bruhn, T; Gieseler, F; Schiller, H; Seifert, A; Zahn, MO | 1 |
| Fuks, J; Hopkins, U; Negassa, A; Perez, A; Ratech, H; Salman, H; Sparano, JA; Villani, G; Wiernik, PH | 1 |
| Bornhäuser, M; Ehninger, G; Illmer, T; Kroschinsky, F; Renner, U; Schaich, M; Schimmelpfennig, C; Schimming, C; Schleyer, E; Trümper, L | 1 |
| Mead, G; Woodcock, J; Young, C | 1 |
| De Propris, MS; De Vellis, A; Gastaldi, R; Gentile, G; Mandelli, F; Martino, P; Pirillo, MF | 1 |
| Aita, P; Basso, B; Boiocchi, M; Corona, G; Ruolo, G; Rupolo, M; Sorio, R; Toffoli, G | 1 |
| Alinari, L; Baccarani, M; Bonifazi, F; Gentilini, P; Guardigni, L; Martelli, M; Molinari, AL; Perrotti, A; Pileri, S; Pulsoni, A; Stefoni, V; Tani, M; Tura, S; Villivà, N; Visani, G; Zinzani, PL | 1 |
| Carella, AM; Dell'Olio, M; Di Renzo, N; La Sala, A; Mele, G; Musto, C; Romano, G; Tartarone, A; Vigliotti, ML | 1 |
| Abali, H; Barista, I; Demirkazik, F; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekin, F; Tekuzman, G; Turker, A; Uner, A | 1 |
| Balestri, F; Biscardi, M; Budriesi, R; Caporale, R; Gavazzi, S; Grossi, A; Scappini, B; Teodori, E | 1 |
| Burton, C; Cunningham, D; Hancock, B; Hoskin, P; Linch, D; Qian, W; Smith, P; Vaughan-Hudson, G | 1 |
| Kansu, E; Kars, A; Koc, Y; Oyan, B; Ozdemir, E; Tekuzman, G; Turker, A | 1 |
| Baldini, L; Brugiatelli, M; Di Renzo, N; Federico, M; Gobbi, PG; Lombardo, M; Luminari, S; Mammi, C; Merli, F; Montanini, A; Partesotti, G; Polimeno, G; Sacchi, S; Stelitano, C | 1 |
| Baldini, L; Balzarotti, M; Bernardi, M; Bobbio, F; Brandes, AA; Caligaris Cappio, F; Corazzelli, G; Dell'Oro, S; Ferreri, AJ; Foppoli, M; Ilariucci, F; Montanari, M; Picozzi, P; Ponzoni, M; Reni, M; Spina, M; Stelitano, C; Tosoni, A; Zaja, F | 1 |
| Angus, B; Galloway, MJ; Jackson, GH; Lessells, AM; Lucraft, HH; Prescott, RJ; Proctor, SJ; Summerfield, GP; Taylor, PR; White, JM | 1 |
| Bárdi, E; Bobok, I; Kappelmayer, J; Kiss, C; V Oláh, A | 1 |
| de Witte, T; Dompeling, E; Donnelly, P; Linssen, P; Minderman, H; Muus, P; Schattenberg, A | 1 |
| Aitini, E; Cajozzo, A; Gentilini, P; Leone, G; Mandelli, F; Papa, G; Rossi, G; Tura, S; Zinzani, PL | 1 |
| Case, DC; Crawford, J; Gams, RA; Gerber, MC; Gould, J; Higano, CS; Pruitt, BT; Votaw, ML | 2 |
| Cajozzo, A; Cantonetti, M; Iannitto, E; Leone, G; Martelli, M; Musso, M; Papa, G; Perrotti, A; Storti, S; Zinzani, PL | 1 |
| Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M | 2 |
| Audhuy, B; Bergerat, JP; Berthaud, P; Dufour, P; Giron, C; Herbrecht, R; Hurteloup, P; Lamy, T; Lioure, B; Maloisel, F; Mors, R; Oberling, F | 1 |
| Kidd, P; Quien, ET; Saidi, P; Sandhaus, L; Strair, R; Wallach, B | 1 |
| Baltes-Engler, S; Dederichs, B; Diehl, V; Engelhard, M; Engert, A; Küpper, F; Lathan, B; Reiser, M; Scheulen, ME; Schnell, R; Tesch, H; Wilhelm, M; Winterhalter, B; Wörmann, B | 1 |
| Amiot, L; Caulet-Maugendre, S; Diebold, J; Drénou, B; Fardel, O; Fauchet, R; Lamy, T; Le Prisé, PY; Sasportes, M | 1 |
| Capochiani, E; Caracciolo, F; Papineschi, F; Petrini, M | 2 |
| Bernengo, MG; Doveil, GC; Fierro, MT; Quaglino, P; Savoia, P; Verrone, A | 1 |
| Albera, C; Bèguelin, R; Cacchione, R; Campestri, R; Dragosky, M; Dupont, J; Fernández, J; Garay, G; Nicastro, M; Noviello, V; Nucifora, E; Riveros, D; Schnidrig, P; Triguboff, E | 1 |
| Avilés, A; Díaz Maqueo, JC; Garcia, EL; Huerta-Guzman, J; Nambo, MJ; Talavera, A | 1 |
| Bernasconi, C; Brusamolino, E; Castagnola, C; Lazzarino, M; Pagnucco, G; Passamonti, F | 1 |
| D'Arco, A; De Renzo, A; Notaro, R; Pagnini, D; Pettinato, G; Pezzullo, L; Rotoli, B | 1 |
| Avanzini, P; Baldini, L; Brugiatelli, M; Carotenuto, M; Clò, V; Di Renzo, N; Dini, D; Federico, M; Gobbi, PG; Lombardo, M; Silingardi, V; Vallisa, D | 1 |
| Borchmann, P; Diehl, V; Engert, A; Münch, R; Reiser, M; Schnell, R; Straub, G; Ubelacker, R; Wilhelm, M; Wörmann, B | 1 |
| Economopoulos, T; Fountzilas, G; Pavlidis, N; Raptis, S; Samantas, E; Xiros, N | 1 |
| Buonaiuto, MR; De Renzo, A; Luciano, L; Notaro, R; Pane, F; Rotoli, B; Santoro, LF | 1 |
| Kuraishi, Y; Masaoka, T; Ogawa, M; Ohashi, Y; Ohno, R; Urabe, A | 1 |
| Devine, S; Heffner, LT; Jones, TW; Lonial, S; Smith, KJ; Waller, EK; Winton, EF; Yeager, AM | 1 |
| Angus, B; Galloway, MJ; Jackson, GH; Proctor, SJ; Soukop, M; Taylor, PR; Tinegate, H | 1 |
| Barbarano, L; Bernuzzi, P; Gargantini, L; Morra, E; Nosari, A; Pungolino, E; Santoleri, L | 1 |
| Kakishita, E; Mori, A; Okada, M; Okamoto, T; Takatsuka, H; Wakae, T | 1 |
| Aleskog, A; Höglund, M; Jonsson, E; Kristensen, J; Larsson, R; Nygren, P; Sundström, C | 1 |
| Crowther, D; Smith, DB; Steward, WP | 1 |
| Carbone, A; Errante, D; Monfardini, S; Sorio, R; Tirelli, U; Zagonel, V | 1 |
| Case, DC; Dorsk, BM; Ervin, TJ; Gams, R; Gerber, M; Hayes, DM | 1 |
| Di Lauro, L; Lopez, M; Papaldo, P | 1 |
3 review(s) available for idarubicin and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Non-hodgkins lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Idarubicin; Ifosfamide; Leucovorin; Lymphoma, Non-Hodgkin; Methotrexate; Prednisolone; Prednisone; Vincristine | 2003 |
Primary central nervous system lymphoma (PCNSL) in immunocompetent adults: analysis of a retrospective series of patients treated using idarubicin-containing regimen and radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Female; Humans; Idarubicin; Immunocompetence; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Remission Induction; Retrospective Studies; Treatment Outcome; Vincristine | 2004 |
Primary extramedullary leukemia of the prostate: case report and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Diagnostic Errors; Doxorubicin; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prostatectomy; Prostatic Neoplasms; Radioisotope Teletherapy; Remission Induction; Urinary Retention; Vincristine | 1996 |
30 trial(s) available for idarubicin and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradiotherapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Immunocompetence; Infections; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neutropenia; Palliative Care; Prednisolone; Recurrence; Remission Induction; Renal Insufficiency; Thrombocytopenia; Treatment Outcome; Vindesine | 2014 |
Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Disease-Free Survival; Female; Humans; Idarubicin; Immunotherapy; Injections, Spinal; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Pilot Projects; Rituximab; Treatment Outcome; Young Adult | 2016 |
Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Remission Induction; Survival Analysis | 2003 |
Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Survival; Etoposide; Half-Life; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Middle Aged; Tumor Cells, Cultured | 2004 |
High dose of idarubicin-based regimen for diffuse large cell AIDS-related non-Hodgkin's lymphoma with or without antiretroviral therapy during antineoplastic agents.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Humans; Idarubicin; Lymphocyte Count; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vincristine | 2003 |
Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aging; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Treatment Outcome; Vidarabine | 2004 |
Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Prednisone; Prognosis; Remission Induction; Treatment Failure; Vincristine | 2005 |
Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Disease-Free Survival; Etoposide; Female; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous | 2005 |
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study.
Topics: Anthracyclines; Epirubicin; Glucuronates; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Prognosis; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome | 2006 |
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Female; Hematologic Diseases; Humans; Idarubicin; Life Tables; Lymphoma, Non-Hodgkin; Male; Meningeal Neoplasms; Methotrexate; Middle Aged; Radiotherapy, Adjuvant; Remission Induction; Stroke; Survival Analysis; Thiotepa | 2006 |
The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphom
Topics: Administration, Oral; Adolescent; Adult; Aged; Chlorambucil; Dexamethasone; Disease Progression; Drug Therapy, Combination; England; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Survival Rate; Time Factors; Treatment Failure | 2006 |
Anthracycline containing regimens in intermediate grade lymphoma. Italian Cooperative Study Group on Intermediate Grade Malignant Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Middle Aged; Prednisolone; Prednisone; Vincristine | 1993 |
Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Idarubicin; Injections, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1993 |
Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Heart Diseases; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Survival Analysis; Vincristine | 1995 |
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Topics: Acute Disease; Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Middle Aged | 1996 |
Idarubicin and high dose cytarabine: a new salvage treatment for refractory or relapsing non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Risk Factors; Salvage Therapy | 1996 |
A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Ifosfamide; Individuality; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1997 |
Consolidation therapy with idarubicin, cisplatin and prednisone (CIP) after P-VABEC regimen in the treatment of intermediate and high grade non-Hodgkin's lymphoma of the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Bone Marrow; Cisplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Life Tables; Lymphoma, Non-Hodgkin; Male; Prednisone; Remission Induction; Survival Analysis; Treatment Outcome; Vincristine | 1997 |
Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Idarubicin; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Recurrence; Salvage Therapy | 1997 |
Epirubicin (CEOP-Bleo) versus idaurubicin (CIOP-Bleo) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma: dose escalation studies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Vincristine | 1997 |
Etoposide and idarubicin in a modified CHOP-like regimen (VICED) for aggressive non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome; Vincristine | 1998 |
Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Heart Diseases; Hematologic Diseases; Humans; Idarubicin; Italy; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Proportional Hazards Models; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 1998 |
DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Etoposide; Female; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Analysis | 1998 |
A phase-II study with idarubicin, etoposide and prednisone (IVPP), in patients with refractory or early relapsed intermediate or high grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Recurrence | 1999 |
[Clinical effect of idarubicin on malignant lymphoma].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Drug Administration Schedule; Drug Evaluation; Female; Hodgkin Disease; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1999 |
High dose chemotherapy without hematopoietic cell support for the treatment of refractory lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Salvage Therapy; Survival Analysis | 2000 |
Primary treatment of low-grade non-Hodgkin's lymphoma using an all oral anthracycline-containing regimen, chlorambucil, idarubicin, dexamethasone (CID)--a phase II study.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Dexamethasone; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis | 2000 |
Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Drug Administration Schedule; Drug Evaluation; Female; Heart Diseases; Humans; Idarubicin; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1992 |
Weekly oral 4-demethoxydaunorubicin in patients with relapsed low grade non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Drug Administration Schedule; Drug Evaluation; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Recurrence, Local | 1991 |
A phase II study of oral idarubicin (4-demethoxidaunorubicin) in previously untreated elderly patients with non-Hodgkin's lymphoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Drug Evaluation; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Neoplasm Staging; Remission Induction | 1991 |
19 other study(ies) available for idarubicin and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin's lymphoma patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Management; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2021 |
CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
Topics: Acute Disease; Aged; Antigens, CD; Antigens, CD7; Antigens, Differentiation, Myelomonocytic; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Cytarabine; Daunorubicin; Diagnosis, Differential; Etoposide; Fatal Outcome; Humans; Idarubicin; Killer Cells, Natural; Leukemia, Myeloid; Leukemic Infiltration; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Mitoxantrone; Myeloid Cells; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma, Myeloid; Sialic Acid Binding Ig-like Lectin 3 | 2002 |
Thrombin as a survival factor for cancer cells: thrombin activation in malignant effusions in vivo and inhibition of idarubicin-induced cell death in vitro.
Topics: Apoptosis; Cell Division; Cell Survival; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Hirudins; HL-60 Cells; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Receptor, PAR-1; Thrombin; Time Factors | 2002 |
Pharmacokinetic comparison of 120-hour infusion versus hyperfractionated oral administration of idarubicin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Area Under Curve; Daunorubicin; Female; Humans; Idarubicin; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged | 2004 |
IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Infections; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome | 2005 |
Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Arrhythmia Agents; Antibiotics, Antineoplastic; Aorta; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Guinea Pigs; Heart Atria; Humans; Idarubicin; K562 Cells; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Organ Culture Techniques; Verapamil | 2006 |
Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer.
Topics: Acetylglucosaminidase; Adolescent; Adult; Albuminuria; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Child; Child, Preschool; Creatinine; Daunorubicin; Doxorubicin; Epirubicin; Female; Humans; Idarubicin; Infant; Kidney Diseases; Kidney Tubules, Proximal; Lymphoma, Non-Hodgkin; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Retrospective Studies | 2007 |
Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Heart; Humans; Idarubicin; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mouth Mucosa; Premedication; Stomatitis; Survival Analysis | 1993 |
CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Transplantation; CD3 Complex; CD56 Antigen; Cell Nucleus; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Female; Femoral Neoplasms; Herpesvirus 4, Human; Humans; Idarubicin; Immunophenotyping; Killer Cells, Natural; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Methylprednisolone; Neoplasm Invasiveness; Neoplasm Proteins; Neoplastic Stem Cells; Pelvic Neoplasms; Prednisone; Quinine; Vincristine | 1997 |
Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Feasibility Studies; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Prednisone; Remission Induction; Sezary Syndrome; Skin Neoplasms; Vincristine | 1997 |
A new effective treatment for indolent lymphoma: a pilot study with fludarabine, idarubicin and prednisone combination (FLIDA).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pilot Projects; Prednisone; Vidarabine | 1997 |
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Chromatography, High Pressure Liquid; Daunorubicin; Half-Life; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Middle Aged; Regression Analysis | 1997 |
Efficacy of a combination of idarubicin, etoposide and intermediate-dose cytosine arabinoside as salvage therapy in relapsing or resistant unfavorable lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Salvage Therapy; Secondary Prevention; Treatment Outcome | 1998 |
Acute promyelocytic leukemia after treatment for non-Hodgkin's lymphoma with drugs targeting topoisomerase II.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Bone Marrow; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Enzyme Inhibitors; Etoposide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Lymphoma, Non-Hodgkin; Middle Aged; Receptors, Retinoic Acid; Recurrence; Topoisomerase II Inhibitors; Translocation, Genetic; Tretinoin | 1999 |
Treatment of patients with high-grade non-Hodgkin's lymphoma aged over 70 years with an all-oral regimen combining idarubicin, etoposide and alkylators.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Agranulocytosis; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Prednimustine; Thrombocytopenia; Treatment Outcome | 2000 |
Secondary acute promyelocytic leukemia in a patient with non-Hodgkin's lymphoma treated with VP-16 and MST-16.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Piperazines; Prednisolone; Remission Induction; Tretinoin; Vincristine | 2002 |
In vitro evaluation of the efficacy of idarubicin in human tumour cells from patients with low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Cell Survival; Female; Humans; Idarubicin; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Tumor Cells, Cultured | 2002 |
Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Drug Evaluation; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Middle Aged | 1990 |
Oral idarubicin in non-Hodgkin's lymphomas.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Blood; Daunorubicin; Female; Heart; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1986 |